Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03270332 · ClinicalTrials.gov registry record · Phase 2
Effect of Inhaled Albuterol in Pulmonary Hypertension
A Phase 2 study, sponsored by University of Miami.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT03270332 is a Phase 2 study that has completed, run by University of Miami. The registered enrollment target is 10 participants.
The verdict
NCT03270332, a Phase 2 study, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of the present pilot study is to test the hypothesis that in patients with group 1 pulmonary arterial hypertension (PAH) who are on regular oral pulmonary vasodilator therapy, inhaled albuterol causes transient pulmonary vasodilation.
Interventions
- DRUG Placebo
- DRUG Albuterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-10-05 |
| Est. Completion | 2020-07-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03270332
The ClinicalTrials.gov registry entry for NCT03270332 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03270332 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03270332 about?
NCT03270332 is a clinical study titled "Effect of Inhaled Albuterol in Pulmonary Hypertension". The purpose of the present pilot study is to test the hypothesis that in patients with group 1 pulmonary arterial hypertension (PAH) who are on regular oral pulmonary vasodilator therapy, inhaled albuterol causes transient pulmonary vasodilation.
What is the current status of trial NCT03270332?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2017-10-05. Estimated completion is 2020-07-02.
What interventions are being tested in trial NCT03270332?
The interventions under investigation include: Placebo (DRUG), Albuterol (DRUG).
Who is sponsoring clinical trial NCT03270332?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.